<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00653549</url>
  </required_header>
  <id_info>
    <org_study_id>01169</org_study_id>
    <nct_id>NCT00653549</nct_id>
  </id_info>
  <brief_title>Bioavailability Study of Torsemide Tablets Under Fasting Conditions</brief_title>
  <official_title>Comparative, Randomized, Single-Dose, 2 Way Cross Over Bioavailability Study of Par Torsemide Tablets 20mg With That of Roche Demadex 1*20 mg in Healthy Subjects Under Fasting Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Par Pharmaceutical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Anapharm</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Par Pharmaceutical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the single-dose bioavailability of Torsemide tablets with Demadex&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare the single -dose bioavailability of Par Torsemide tablets 20mg with that Roche&#xD;
      Demadex 1*20mg tablets under fasting conditions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2001</start_date>
  <completion_date type="Actual">May 2001</completion_date>
  <primary_completion_date type="Actual">May 2001</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate and Extend of Absorption</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>To Determine Bioequivalence Under Fasting Conditions</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received Par formulated product under fasting conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received Roche formulated product under fasting conditions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Torsemide</intervention_name>
    <description>Tablets, 20 mg, single-dose</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Demadex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Demadex</intervention_name>
    <description>tablets, 20 mg, single-dose</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Torsemide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects enrolled in the study will be members of the community at large.&#xD;
&#xD;
          -  The Recruitment will be done by radio, newspapers and Anapharm Inc.&#xD;
&#xD;
          -  Anapharm Website advertisements.&#xD;
&#xD;
          -  Subjects must meet all the following criteria in order to be included in the study.&#xD;
&#xD;
          -  Subjects will be male and / or female, smokers and non-smokers, 18 years of age and&#xD;
             older.&#xD;
&#xD;
          -  Subjects should read, sign, and date an Informed Consent form prior to the study&#xD;
             procedures.&#xD;
&#xD;
          -  Subjects must complete all screening procedures within 28 days prior to the&#xD;
             administration of the study medication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Breast- feeding female subjects.&#xD;
&#xD;
          -  Any clinically significant abnormality found during medical screening.&#xD;
&#xD;
          -  Subjects with BMI â‰¥30&#xD;
&#xD;
          -  Any Clinically significant gastrointestinal pathology (e.g. chronic diarrhea,&#xD;
             inflammatory bowel diseases) or unresolved gastrointestinal symptoms (e.g. diarrhea,&#xD;
             vomiting), susceptible of interfering with the absorption of drugs.&#xD;
&#xD;
          -  Clinically significant illness within 4 weeks prior to the administration of the study&#xD;
             medication&#xD;
&#xD;
          -  Abnormal laboratory tests judged clinically significant.&#xD;
&#xD;
          -  ECG abnormalities (clinically significant) (PR interval greater than 225ms);or vital&#xD;
             sign abnormalities (systolic blood pressure lower than 90 or over 140 mmHg, diastolic&#xD;
             blood pressure lower than 60 or over 95 mmHg, or heart rate less than 60 bpm) at&#xD;
             screening.&#xD;
&#xD;
          -  History of allergic reactions to torsemide or sulfonylureas (e.g. tolbutamide,&#xD;
             chlorpropamide, glyburide and gliclazide) or other related drugs ( e.g. furosemide,&#xD;
             bumetanide, sulfabenzamide, sulfacetamide, sulfathiazole, sulfadiazine,&#xD;
             sulfamethoxazole, sulfasalazine, sulfisoxazole and dapsone).&#xD;
&#xD;
          -  Any food allergy, intolerance, restriction or special diet that, in the opinion of the&#xD;
             Medical Sub- Investigator, could contraindicate the subject's participation in this&#xD;
             study.&#xD;
&#xD;
          -  Positive urine drug screen at screening.&#xD;
&#xD;
          -  Positive testing for hepatitis B, hepatitis C, or HIV at screening.&#xD;
&#xD;
          -  Positive urine pregnancy test at screening.(performed on all female subjects)&#xD;
&#xD;
          -  Use of an investigational drug or participation in an investigational study within 30&#xD;
             days prior to administration of the study medication.&#xD;
&#xD;
          -  Donation of plasma ( 500 mL) within 7 days or donation of significant loss of whole&#xD;
             blood (450 mL) within 56 days prior to administration of the study medication.&#xD;
&#xD;
          -  History of significant alcohol abuse within six months of the screening visit or any&#xD;
             indication of the regular use of more than two units of alcohol per day (1 Unit = 150&#xD;
             mL of wine or 360 mL of beer or 45 ml of alcohol 40%)&#xD;
&#xD;
          -  History of drug abuse or use of illegal drugs: Use of soft drugs (such as marijuana,&#xD;
             pot) within 3 months of the screening visit or hard drugs (such as cocaine,&#xD;
             phencyclidine [PCP] and crack) within 1 year of the screening visit.&#xD;
&#xD;
          -  Subjects who have taken prescription medication within 14 days prior to administration&#xD;
             of study medication or over the counter products within 7 days prior to administration&#xD;
             of study medication, except for topical products without systemic absorption.&#xD;
&#xD;
          -  Female subjects of childbearing potential having unprotected sexual intercourse with&#xD;
             any non- sterile male partner (i.e. male who has not been sterilized by vasectomy for&#xD;
             al least 6 months) within 14 days prior to study drug administration. The Acceptable&#xD;
             methods of contraception are :&#xD;
&#xD;
          -  Condom+ spermicide (within 14 days prior to study drug administration)&#xD;
&#xD;
          -  Diaphragm + spermicide (within 14 days prior to study drug administration.&#xD;
&#xD;
          -  Intrauterine contraceptive device (place al least 4 weeks prior to study drug&#xD;
             administration)&#xD;
&#xD;
          -  Subjects who have taken any drugs known to induce or inhibit hepatic drug metabolism&#xD;
             within 30 days prior to administration of the study medication.&#xD;
&#xD;
          -  (examples of inducers: barbiturates, carbamazepine, phenytoin,glucocorticoids,&#xD;
             rifampin,rifabutin; examples of inhibitors: antidepressants, cimetidine, diltiazem,&#xD;
             erythromycin, ketoconazole, MAO inhibitors, neuroleptics, verapamil, quinidine)&#xD;
&#xD;
          -  Subjects who have undergone clinically significant surgery within 4 weeks prior to the&#xD;
             administration of the study medication.&#xD;
&#xD;
          -  Any reason which, in the opinion of the investigator, would Prevent the subject from&#xD;
             participating in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Masson</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anapharm</affiliation>
  </overall_official>
  <verification_date>June 2011</verification_date>
  <study_first_submitted>April 1, 2008</study_first_submitted>
  <study_first_submitted_qc>April 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2008</study_first_posted>
  <last_update_submitted>June 16, 2011</last_update_submitted>
  <last_update_submitted_qc>June 16, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Alfred Elvin/ Director Biopharmaceutics</name_title>
    <organization>Par Pharmaceutical, Inc.</organization>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Torsemide Tablets</keyword>
  <keyword>fasting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Torsemide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

